title: Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure.
abstract: BACKGROUND
  Spironolactone was shown to reduce mortality in patients with heart failure (HF). However, the effect of spironolactone on the incidence of atrial fibrillation remains unknown. Therefore, we examined the effects of spironolactone on atrial conduction and remodeling in patients with HF.
  
  
  RESULTS
  A total of 21 patients with HF were divided into either spironolactone group (n=11) or control group (n=10). The patients were followed up for 12 months. Blood examination, echocardiogram, and signal-averaged electrocardiogram were performed at study enrollment and after 3 and 12 months of treatment. In the spironolactone group, atrial natriuretic peptide tended to reduce, left atrium dimension was significantly smaller, the ratio of E wave to A wave tended to improve, and P-duration was significantly shortened.
  
  
  CONCLUSIONS
  Spironolactone improves atrial conduction and remodeling in patients with HF.
authors.affiliation: Division of Cardiology, Tokuyama Central Hospital, Kouda-cho 1-1, Shunan, Yamaguchi 745-8522, Japan. kimura@mu.0038.net
authors.forename: Masayasu
authors.initials: M
authors.lastname: Kimura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ogawa
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Wakeyama
authors.forename: Akira
authors.initials: A
authors.lastname: Takaki
authors.forename: Takahiro
authors.initials: T
authors.lastname: Iwami
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Hadano
authors.forename: Mamoru
authors.initials: M
authors.lastname: Mochizuki
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hiratsuka
authors.forename: Akihiko
authors.initials: A
authors.lastname: Shimizu
authors.forename: Masunori
authors.initials: M
authors.lastname: Matsuzaki
mesh_terms: D000368:Aged; D004452:Echocardiography; D005260:Female; D006325:Heart Atria / Q000503:physiopathology; D006329:Heart Conduction System / Q000503:physiopathology*; D006333:Heart Failure / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone / Q000008:administration & dosage*; D020257:Ventricular Remodeling
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone